Anti-egfr antibodies and antibody drug conjugates

Abstract

The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

1 . An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising
 a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 12, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 11, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 20; and   a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 28, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 27, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 26,   wherein the antibody is an IgG isotype.   
     
     
         2 . The antibody of  claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 76, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 77. 
     
     
         3 . An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising
 a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 22, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 3, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 21; and   a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 31, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 30, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 29,   wherein the antibody is an IgG isotype.   
     
     
         4 . The antibody of  claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 78, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 79. 
     
     
         5 . A method for treating a subject having cancer, comprising administering an effective amount of an antibody drug conjugate (ADC) comprising an anti-EGFR antibody conjugated to at least one auristatin, wherein the anti-EGFR antibody is an IgG isotype; comprises a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 12, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 11, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 10; and comprises a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 8, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 7, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 6.